Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Basks In Good News, But Here Is Something To Remember

by Tom Kelly | Wednesday, Mar 12, 2014 | 579 views

Boston, MA, 03/12/2014 – Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is all excitement after good news emerged that Germany has granted the company special hospital exemption for its brain cancer drug. This move not only signals a break from the norm in Germany’s health sector, but also provides a wonderful revenue opportunity for the company. However, just before you jump in celebration, there is something important to note. More about that in a short while, now let’s take a recap of the shares performance in the last trading day.

Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) were traded in the range of $8.25 – $10.64, thus touching a new 52-week high. The day was characterized with large volume trading and at the end of the session shares were up 16.93 percent to $9.18.

Something to keep in mind

Although Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has had its brain cancer drug offered special entry into Germany’s hospitals and outpatient clinics, the drug is yet to get approval from the U.S. Food and Drug Administration. In any case, the interim data from late-stage trail of the drug are behind schedule in that they were expected in last month.

Germany jumps gun

By granting permission to DCVax-L for treatment of brain cancer patients in its territory, Germany seems to suggest a lot of hope for the drug even if important study is still underway. The move by Germany to accept DCVax-L into its health facilities mirrors the encouragement of the European Union to its member countries to provide hospital exemptions as a way to support breakthrough treatment technologies.

Investor Takeaway

There is no doubt that the Germany’s special hospital exemption offers a great opportunity for Northwest Biotherapeutics, Inc (NASDAQ:NWBO) to generate revenue with its brain cancer drug even as it awaits its late-stage study results. Also, the German permission has the potential of opening such opportunities in other EU countries. Yet, wise investors should not go full swing in the stock as it is important to keep an eye in the upcoming trail results, lest they alter the landscape.

Like it? Share it!

Leave A Response